Table 2.

Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for the Assessment of HCC Response to Locoregional and Systemic Therapy.

Assessment category	mRECIST criteria
CR (complete response)	Disappearance of any intratumoral arterial enhancement in all target lesions
PR (partial response)	At least 30% decrease in the sum of diameters of viable target lesions
SD (stable disease)	Any cases that do not qualify for either PR or PD
PD (progressive disease)	At least 20% increase in the sum of the diameters of viable target lesions

HCC, hepatocellular carcinoma.